治疗靶点专家意见 SCIE

期刊简介预计审稿时间： 偏慢,4-8周

The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials.

The Editors welcome:

Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.

Articles should not include clinical information including specific drugs and clinical trials.

Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.

The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.

本期刊评估分子、信号通路、受体和其他治疗靶点及其作为药物开发候选物的潜力。本期刊上的文章侧重于分子水平和早期临床前研究。文章不应包括临床信息，包括特定药物和临床试验。

编辑欢迎：

涵盖分子水平的新疾病靶点的评论以及有关早期临床前研究及其对未来药物开发的影响的信息。

文章不应包括临床信息，包括特定药物和临床试验。

原创研究论文，报告靶点选择和验证研究的结果以及研究和上市药物的基本作用机制研究。

读者包括制药行业的科学家、管理人员和决策者、分子医学领域的学术研究人员以及其他密切参与研发的人员。

《Expert Opinion On Therapeutic Targets》(治疗靶点专家意见)编辑部通讯方式为INFORMA HEALTHCARE, TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON, ENGLAND, EC2A 4LQ。如果您需要协助投稿或润稿服务，您可以咨询我们的客服老师。我们专注于期刊投稿服务十年，熟悉发表政策，可为您提供一对一投稿指导，避免您在投稿时频繁碰壁，节省您的宝贵时间，有效提升发表机率，确保SCI检索（检索不了全额退款）。我们视信誉为生命，多方面确保文章安全保密，在任何情况下都不会泄露您的个人信息或稿件内容。